Slide 1: Precision Medicine in Neuroscience
Precision Medicine in Neuroscience Final results for year ending 30 September 2024 DEC 2024
Slide 2: Nonregulated Disclaimer
Nonregulated Disclaimer This presentation is incomplete without reference to, and should be viewed solely in conjunction with, the oral briefing which accompanies it. The information in this presentation is subject to updating, revision and amendment. The information in this presentation, which incl
Slide 3: IXICO at a glance
IXICO at a glance Track record in advanced neuroimaging solutions that unlock the power of medical imaging data with AI 15-year track record in medical imaging data curation and analytics Currently 25 In past 5 years studies with Demonstrated history 18 clients in Neuroscience worldwide >70 worked w
Slide 4: USP: deriving novel insights from imaging biomarkers
USP: deriving novel insights from imaging biomarkers Accelerating biopharma’s abilities to access precision medicine in neurology, progressing disease understanding and drug development. Market leading technology that helps biopharma make informed "high stake" program decisions to accelerate or fail
Slide 5: Technological Edge: powerful AI platform
Technological Edge: powerful AI platform An end-to-end platform enabling precision insight generation from neuro-imaging Regulatory-compliant, scalable data management platform iCRO Service Delivery Trial Tracker Analysis deployment • Patient eligibility & Standardized, high- stratification • Treatm
Slide 6: Commercial & Operational highlights FY 2024
Commercial & Operational highlights FY 2024 Commercial, scientific, operations and innovations foundations reset to define new path towards sustainable performance at scale Foundational reset has led to robust commercial recovery in H2 Imeka >£1m AD Collaboration contract HD-IH partner TTNx platform
Slide 7: Strengthened Leadership Team
Strengthened Leadership Team Bram Goorden, CEO Mark Warne, Board Chair Dipti Amin, NED • 20+ years of experience - CNS, • Widely recognised in the UK and • Commercial and operational precision medicine, platform international life sciences sector leadership with over 20 years of innovation an execut
Slide 8: Financial Results
Financial Results FINAL RESULTS FY2024 | © IXICO PLC FINAL RESULTS FY2024 | © IXICO PLC DEC 2024
Slide 9: H2 revenue growth plus cost control delivers EBITDA ahead of guidance
H2 revenue growth plus cost control delivers EBITDA ahead of guidance. Revenues (£m) Gross Margin (%) EBITDA (£m) 98 FTEs 61 1.5 72 5.8 49 47 8.6 3.3 H2 6.7 -0.8 2.5 H1 -1.7 2022 2023 2024 2022 2023 2024 2022 2023 2024 ▪ Weaker H1 due to industry trading conditions ▪ Gross margins stabilised and rem
Slide 10: Well capitalised and key technology investment complete
Well capitalised and key technology investment complete Cash (£m) Capital investment (£m) Net Assets (£m) 2.3 1.9 12.5 5.8 5.7 11.4 9.5 4.0 1.8 0.5 2022 2023 2024 Oct-24 2022 2023 2024 2022 2023 2024 ▪ £1.8m debt-free cash position ▪ Large reduction in capital investment ▪ Strong balance sheet ▪ Aug
Slide 11: Expanding order book points to return to growth
Expanding order book points to return to growth Order Book (£m) 16.0 15.3 5.8 14.8 8.9 14.8 2.6 15.3 2022 2023 2024 30-Sep-23 Revenues Client trial Trial wins 30-Sep-24 descopes and fx ▪ £15.3m of future years’ revenues contracted at 30-Sep- ▪ £8.9m contract wins; new contracts across 11 clients, co
Slide 12: Highly diversified order book with multiple 'shots on goal'
Highly diversified order book with multiple ‘shots on goal’ 100% By clinical trial phase By therapeutic indication 90% 0.7 (3) 1.6 2.9 80% 3.8 (2) (6) 5.2 (8) (7) 70% 2.9 (5) 0.8 (1) 60% By project £m 4.8 7.9 50% (8) (10) 40% £m/(#) £m/(#) 1 2 3 NH Other AD HD PD Other 30% 20% ▪ 18 clients, 25 proje
Slide 13: Growth Strategy
© X C O P L C 2 0 2 4 Growth Strategy FINAL RESULTS FY2024 | © IXICO PLC DEC 2024
Slide 14: Growth Strategy: 'Innovate Lead Scale' Strategy
Growth Strategy: ‘Innovate Lead Scale’ Strategy’ Broadening and deepening the commercial opportunity to drive growth • DIFFERENTIATION - novel biomarker analytics market leadership ACCELERATE GROWTH • TECHNOLOGY EXPANSION - next-gen AI-powered imaging biomarker platform (TTNx) and access to real INN
Slide 15: Growth Strategy: accelerating innovation to drive commercial growth
Growth Strategy: accelerating innovation to drive commercial growth Differentiation through the application of proven IXIQ.Ai analytics platform in AD and PD 1. Leverage unique data assets 2. Obtain endorsement from thought leaders 3. Engage with Consortia and Pharma FY 2025 *Continued investment as
Slide 16: Growth Strategy: Addressable Market Expansion
Growth Strategy: Addressable Market Expansion Increasing our serviceable pool of disease areas Development Roadmap Next generation AI powered biomarkers services to address a larger proportion of the global neuroimaging clinical trials market Implement knowledge gained as a bridge into post marketin
Slide 17: Next steps: FY25 activity
Next steps: FY25 activity Sound financial growth and a strengthened balance sheet Differentiation in AD & PD • Delivery of new IXIQ.Ai features INNOVATE • KOLs for each innovation theme actively endorsing IXICO • Increase AD & PD awards volume Respected voice in CNS imaging • Increase share of voice
Slide 18: Growing the organisation for scale
Growing the organisation for scale CEO Key drivers: CoS | Corp Dev • CSO / CMO (new) appointment to drive INNOVATE | LEAD CFO / COO CSO / CMO CCO HR QA / RA • Medical affairs / thought leadership staff Bus. Dev. Int’l Finance R&D + NorAm • “Chief Commercial Officer” driving BD (North America) and cu
Slide 19: Investment case
Investment case ✓ Market leading technology – market leader in imaging for HD and rare disease clinical trials, high scarcity value as a leading neuroimaging platform with cutting edge technology ✓ Clear strategy to increase market – Identified an estimated 3x bigger serviceable market through strat
Slide 20: Thank you
Thank you www.ixico.com © IXICO PLC 2024 DEC 2024
Slide 21: Major shareholders (>3% holding)
Major shareholders (>3% holding) Percentage Shareholder Date first invested No. of Shares allocation Octopus Investments May-18 16,850,400 18.2% Gresham House May-18 16,428,100 17.7% BGF Investment Management May-19 12,887,000 13.9% Amati Global Investors May-18 8,606,300 9.3% Canaccord Genuity Asse
Slide 22: Summary Income Statement
Summary Income Statement Income Statement FY2022 FY2023 FY2024 £’000 £’000 £’000 Revenues 8,643 6,665 5,766 YoY% decline -6.0% -22.9% -13.5% Gross profit 5,243 3,270 2,711 Gross margin % 60.7% 49.1% 47.0% Other income 689 393 781 R&D (1,217) (925) (1,337) S&M (1,226) (1,321) (1,396) G&A (2,581) (2,8
Slide 23: Summary Balance Sheet
Summary Balance Sheet Balance Sheet FY2022 FY2023 FY2024 £’000 £’000 £’000 Tangible & intangible assets 5,404 6,704 6,696 Other current and non-current assets 3,482 2,255 2,705 Cash 5,769 4,031 1,787 Current liabilities (1,735) (1,281) (1,574) Total working capital 7,516 5,005 2,918 Non-current liab
Slide 24: Summary Cashflow
Summary Cashflow Cashflow FY2022 FY2023 FY2024 £’000 £’000 £’000 Cashflow from operating 1,424 302 (1,732) Cashflow from investing (2,239) (1,864) (377) Cashing flow from financing (114) (156) (134) Movement in cash (929) (1,718) (2,243) Opening cash 6,684 5,769 4,031 Effect of FX 14 (20) (1) Closin